A Balanced, Randomized, Placebo-Controlled, Double-Blind Study of the Efficacy and Safety of AUT00063 Versus Placebo in Age-Related Hearing Loss [CLARITY-1 Study]
Phase of Trial: Phase II
Latest Information Update: 21 Sep 2017
At a glance
- Drugs AUT 00063 (Primary)
- Indications Hearing loss
- Focus Therapeutic Use
- Acronyms CLARITY-1
- Sponsors Autifony Therapeutics
- 14 Sep 2016 Status changed from active, no longer recruiting to completed.
- 18 Apr 2016 Status changed from recruiting to active, no longer recruiting.
- 24 Nov 2015 Planned End Date changed from 1 Mar 2016 to 1 Jul 2016 as reported by ClinicalTrials.gov record.